{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+solution&page=12", "query": { "intervention": "Placebo solution", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 3135, "total_pages": 314, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+solution&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+solution&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T05:12:49.275Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06310200", "title": "Sphenopalatine Ganglion Block and Cold Induced Headaches", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cold Induced Headache", "Brain Freeze", "Cold Induced Cephalgia", "Headache" ], "interventions": [ { "name": "Lidocaine Topical 4% Topical Solution", "type": "DRUG" }, { "name": "Bitrex", "type": "DRUG" }, { "name": "normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wright State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-01-01", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2025-01-31", "last_synced_at": "2026-10-18T05:12:49.275Z", "location_count": 1, "location_summary": "Dayton, Ohio", "locations": [ { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06310200" }, { "nct_id": "NCT01393600", "title": "NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tardive Dyskinesia" ], "interventions": [ { "name": "NBI-98854", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurocrine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2011-08", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2017-08-10", "last_synced_at": "2026-10-18T05:12:49.275Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • National City, California • San Diego, California + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "National City", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01393600" }, { "nct_id": "NCT00811395", "title": "Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Teriflunomide", "type": "DRUG" }, { "name": "Placebo (for teriflunomide)", "type": "DRUG" }, { "name": "Interferon-β [IFN-β]", "type": "DRUG" }, { "name": "Glatiramer Acetate [GA]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 182, "start_date": "2007-10", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2012-12-31", "last_synced_at": "2026-10-18T05:12:49.275Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00811395" }, { "nct_id": "NCT04173819", "title": "Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "3BNC117-LS-J", "type": "BIOLOGICAL" }, { "name": "10-1074-LS-J", "type": "BIOLOGICAL" }, { "name": "Combination 3BNC117-LS-J and 10-1074-LS-J", "type": "BIOLOGICAL" }, { "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1", "type": "BIOLOGICAL" }, { "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2", "type": "BIOLOGICAL" }, { "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "International AIDS Vaccine Initiative", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 225, "start_date": "2019-01-25", "completion_date": "2023-09-01", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-10-18T05:12:49.275Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Seattle, Washington", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04173819" }, { "nct_id": "NCT03994731", "title": "Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Gout" ], "interventions": [ { "name": "Pegloticase", "type": "BIOLOGICAL" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "folic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "gout flare prophylaxis regimen", "type": "DRUG" }, { "name": "fexofenadine", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2019-06-13", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-18T05:12:49.275Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03994731" }, { "nct_id": "NCT00643201", "title": "Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thrombosis" ], "interventions": [ { "name": "Enoxaparin", "type": "DRUG" }, { "name": "warfarin", "type": "DRUG" }, { "name": "Placebo for apixaban", "type": "DRUG" }, { "name": "Placebo for enoxaparin", "type": "DRUG" }, { "name": "Placebo for warfarin", "type": "DRUG" }, { "name": "apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5614, "start_date": "2008-07", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-10-18T05:12:49.275Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Banning", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00643201" }, { "nct_id": "NCT03934710", "title": "Mood Effects of Serotonin Agonists Extended", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Serotonin agonist - 13ug", "type": "DRUG" }, { "name": "Serotonin agonist - 26ug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 56, "start_date": "2019-04-20", "completion_date": "2021-06-07", "has_results": true, "last_update_posted_date": "2023-11-29", "last_synced_at": "2026-10-18T05:12:49.275Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03934710" }, { "nct_id": "NCT03960541", "title": "Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Dyslipidemias" ], "interventions": [ { "name": "Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)", "type": "DRUG" }, { "name": "Saline Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 8, "start_date": "2020-08-31", "completion_date": "2021-05-27", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-18T05:12:49.275Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03960541" }, { "nct_id": "NCT05731128", "title": "A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colitis Ulcerative" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2023-01-12", "completion_date": "2027-02-22", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-18T05:12:49.275Z", "location_count": 27, "location_summary": "Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more", "locations": [ { "city": "Apple Valley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Thousand Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05731128" }, { "nct_id": "NCT05039359", "title": "Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Paroxysmal Atrial Fibrillation" ], "interventions": [ { "name": "FlecIH-103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InCarda Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 54, "start_date": "2022-04-26", "completion_date": "2023-05-22", "has_results": false, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-10-18T05:12:49.275Z", "location_count": 18, "location_summary": "Davis, California • Long Beach, California • Bridgeport, Connecticut + 12 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039359" } ] }